ライフサイエンスコーパス: LUTS

1 LUTS cases had at least three of these symptoms: nocturi

2 LUTS cases were defined as men who reported surgery for

3 LUTS specific quality of life, incontinence, and percept

4 LUTS usually manifest as urgency, urinary frequency, inc

5 LUTS were common both before and after RTx as measured b

6 LUTS/BPH is an independent risk factor for sexual dysfun

7 rs; standard deviation [SD], 16.5 years), 30 LUTS patients on treatment (mean age, 47.8 years; SD, 16

8 udy was conducted on urine specimens from 33 LUTS patients attending their first clinical appointment

9 ion limits our ability to clinically address LUTS.

10 ejaculation frequency in early adulthood and LUTS.

11 - for the prevention or treatment of BPH and LUTS have yet to be performed.

12 e for the prevention or treatment of BPH and LUTS have yet to be performed.

13 antly increased risks of symptomatic BPH and LUTS include obesity and consumption of meat and fat.

14 for the prevention and treatment of BPH and LUTS while positively affecting other systemic parameter

15 for the prevention and treatment of BPH and LUTS, nutritional modifications may have a healthy lifes

16 ially alter the risks of symptomatic BPH and LUTS.

17 standard treatments for symptomatic BPH and LUTS.

18 ity - both of which inversely effect BPH and LUTS.

19 and dietary supplements in men with BPH and LUTS.

20 ow-up, and between 5-year intake changes and LUTS progression.

21 f weight loss in obese men with diabetes and LUTS and dietary modification has also been shown to be

22 may contribute to the link between diet and LUTS because of their anti-inflammatory potential, and 3

23 he association between lifestyle factors and LUTS and the effect of lifestyle modification on the dev

24 ute associations between beverage intake and LUTS in the Boston Area Community Health (BACH) cohort (

25 olume, prostate-specific antigen levels, and LUTS as well as rapid decreases in peak flow rates (thro

26 prescription and over-the-counter NSAIDs and LUTS among 1,974 men and 2,661 women in the Boston Area

27 upport for an association between NSAIDs and LUTS.

28 uency, surgery for an enlarged prostate, and LUTS.

29 Information on prostate surgery and LUTS was updated every 2 years.

30 oda, had higher symptom scores, urgency, and LUTS progression.

31 ve been proposed for the association between LUTS and male sexual dysfunction.

32 d strong evidence for an association between LUTS, erectile dysfunction and ejaculatory dysfunction.

33 Recent evidence of an association between LUTS/BPH and sexual dysfunction will be reviewed, as wel

34 Owing to the link between LUTS/BPH and male sexual dysfunction, patients presentin

35 the mechanism(s) underlying the link between LUTS/BPH and male sexual dysfunction.

36 1077 men (>=18 years) with bothersome LUTS recruited between June 2018 and August 2019: 524 we

37 ationship between metabolic syndrome and BPH/LUTS, indicating a common cause.

38 the components of metabolic syndrome and BPH/LUTS.

39 ocuses on the use of PDE5 inhibitors for BPH/LUTS treatment and highlights the clinical significance.

40 and well tolerated treatment option for BPH/LUTS.

41 kers resulted in greater improvements in BPH/LUTS than did either drug alone.

42 osphate/PDE5 pathway in the treatment of BPH/LUTS deserve further investigations.

43 activity, appear to decrease the risk of BPH/LUTS.

44 ay have an additive beneficial effect on BPH/LUTS compared with monotherapy.

45 t in the use of PDE5 inhibitors to treat BPH/LUTS.

46 tion to other conditions that may be causing LUTS.

47 rvoirs, but the role of infection in chronic LUTS is unknown.

48 biome, in conditions associated with chronic LUTS.

49 ype 5 inhibitors in patients with coexisting LUTS and erectile dysfunction.

50 f functional constipation, animals developed LUTS including urinary frequency and detrusor overactivi

51 gnificantly increases the risk of developing LUTS/BPH among middle-aged and elderly men in China.

52 a significantly increased risk of developing LUTS/BPH compared to matched controls (OR = 1.530, P = 0

53 atic controls, confirming MUFS is a distinct LUTS symptom complex.

54 r age, comorbidities, and lifestyle factors, LUTS have been clearly demonstrated to be an independent

55 linical trials of antiinflammatory drugs for LUTS have been largely unsuccessful, the role of inflamm

56 ons to limit caffeinated beverage intake for LUTS, and in men, they suggest benefits of citrus juice

57 odds ratios and 95% confidence intervals for LUTS, voiding symptoms, storage symptoms, and nocturia.

58 uidelines as the first-line intervention for LUTS.

59 conservative and lifestyle interventions for LUTS in men.

60 sed to identify patients at highest risk for LUTS after RTx.

61 to determine if patients at highest risk for LUTS could be predicted by validated questionnaires or o

62 physical activity level and a lower risk for LUTS or progression of LUTS, 2) certain specific nutrien

63 lopment of a urine-based diagnostic test for LUTS.

64 as a minimally invasive surgical therapy for LUTS associated with benign prostatic hyperplasia seems

65 dditional studies of combination therapy for LUTS/BPH, sexual dysfunction, and other age-associated c

66 because medical and surgical treatments for LUTS/BPH are commonly associated with sexual side effect

67 nce (> or = 102 cm) were more likely to have LUTS compared with men with a smaller waist circumferenc

68 p to 15% to 25% of men aged 50-65 years have LUTS of sufficient severity to interfere with their qual

69 41%) were HIV positive and 14 (7.57%) having LUTS.

70 s suggestive of benign prostate hyperplasia (LUTS/BPH) are both common chronic conditions among middl

71 suggestive of benign prostatic hyperplasia (LUTS/BPH).

72 he treatment of benign prostatic hyperplasia/LUTS can be properly assessed.

73 elling men with benign prostatic hyperplasia/LUTS.

74 n these hormones, and the rates of change in LUTS, maximum urinary flow rate, and prostate volume.

75 time were associated with rapid increases in LUTS and rapid decreases in maximum flow rate.

76 primary care showed a sustained reduction in LUTS in men at 12 months.

77 es regarding the outcome of thermotherapy in LUTS/BPH patients.

78 ios and 95% confidence intervals of incident LUTS (from no or a low International Prostate Symptom Sc

79 d a significantly increased risk of incident LUTS/BPH after seven years of follow-up (OR = 1.531, P <

80 imilarly showed an elevated risk of incident LUTS/BPH in arthritis patients compared to controls (OR

81 ypertension, and smoking history (irritative LUTS: OR = 2.00, 95% CI: 1.04, 3.82; peak flow rate: OR

82 likely to have rapid increases in irritative LUTS (odds ratio (OR) = 2.14, 95% confidence interval (C

83 s suggest that rapid increases in irritative LUTS and rapid decreases in peak flow rates may be due t

84 id increases in prostate volume, obstructive LUTS, or prostate-specific antigen levels.

85 >/=15; n = 5,790 cases in 24,715 men) and of LUTS progression (from modest IPSS of 8-14 to severe IPS

86 life will demand that we unlock the cause of LUTS secondary to BPH with the goal of prevention as the

87 ially influence the development or course of LUTS.

88 tions may contribute to later development of LUTS, although confirmation in additional population set

89 terations and support objective diagnosis of LUTS.

90 ssion, understanding that the improvement of LUTS relief should be weighed with the potential risks o

91 are important steps in medical management of LUTS.

92 ine intake at baseline increased the odds of LUTS progression in men (coffee: >2 cups/day vs. none, o

93 intake was associated with 50% lower odds of LUTS progression in men (P = 0.02).

94 The odds of LUTS were lower for men who were obese at age 25 years c

95 ity of life, incontinence, and perception of LUTS also improved more in the intervention arm than usu

96 of life, urinary symptoms and perception of LUTS, hospital referrals, and adverse events.

97 may be associated with a lower prevalence of LUTS later in life, whereas weight gain and central adip

98 The prevalence of LUTS secondary to BPH and prostate cancer both increase

99 sibly associated with a higher prevalence of LUTS.

100 between baseline intakes and progression of LUTS at 5-year follow-up, between follow-up intakes and

101 and a lower risk for LUTS or progression of LUTS, 2) certain specific nutrients or dietary factors m

102 ication on the development or progression of LUTS.

103 may decrease the incidence or progression of LUTS.

104 ay inhibit the development or progression of LUTS.

105 The hazard ratios of LUTS incidence and progression comparing current use to

106 ividuals with arthritis had a higher risk of LUTS/BPH than those without arthritis (OR = 1.483, P < 0

107 s to determine the frequency and severity of LUTS in RTx patients and to determine if patients at hig

108 eness of PDE5 inhibitors in the treatment of LUTS secondary to BPH.

109 the first characterization and validation of LUTS urinary metabolites and pathways to support the fut

110 Women >=65 years with >=2 new-onset LUTS and 1 uropathogen >=104 colony-forming units (CFU)/

111 with laboratory markers specific for BPH or LUTS is currently inadequate.

112 t in men with urinary incontinence and other LUTS.

113 tween over-the-counter NSAID use and overall LUTS among women with a history of arthritis (odds ratio

114 IDs (compared with no NSAID use) and overall LUTS, voiding symptoms, or nocturia in men or women.

115 commonly associated with chronic, persistent LUTS and present the limitations of current diagnostic p

116 t only for potentially improving or reducing LUTS but also for cardiovascular and overall health.

117 ion for patients presenting with BPH-related LUTS, and suggest novel treatment strategies.

118 all been shown to be effective in relieving LUTS/BPH independent of prostate size.

119 so predictive of moderate to severe post-RTx LUTS (relative risk, 2.9-5.9; P<0.02).

120 re predictive of moderate to severe post-RTx LUTS (relative risk, 4.1-18.0; P</=0.05).

121 enlarged prostate or high-moderate to severe LUTS (> or = 15 points on the American Urological Associ

122 were at increased risk of moderate to severe LUTS, including obstructive symptoms.

123 putative risk factors for moderate to severe LUTS, including subcategories of obstructive and irritat

124 l history risk factors in moderate to severe LUTS, including the subcategories of obstructive and irr

125 ation therapy in men with moderate-to-severe LUTS, reduced urinary flow rate, and no prior BPH interv

126 ions between BPH with clinically significant LUTS, the metabolic syndrome, inflammation, alterations

127 chotomized afferents, could underlie storage LUTS in symptomatic BPH with prostatic inflammation.

128 acological treatment options for symptomatic LUTS/BPH on sexual function.

129 Administration for treatment of symptomatic LUTS/BPH: terazosin, doxazosin, tamsulosin, alfuzosin an

130 lower urinary tract [obstructive] symptoms (LUTS) may benefit from a similar discussion, understandi

131 that describes lower urinary tract symptoms (LUTS) accompanied by abnormal bowel patterns manifested

132 Lower urinary tract symptoms (LUTS) are a common condition, particularly among older m

133 Lower urinary tract symptoms (LUTS) are a range of irritative or obstructive symptoms

134 Lower urinary tract symptoms (LUTS) are exceptionally common and debilitating, and the

135 Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)

136 s with chronic lower urinary tract symptoms (LUTS) below the diagnostic cutoff on MSU culture may sti

137 and associated lower urinary tract symptoms (LUTS) commonly affect older men.

138 Worldwide, lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) is a com

139 sk factors for lower urinary tract symptoms (LUTS) have focused on White populations.

140 ic hyperplasia/lower urinary tract symptoms (LUTS) in 2014.

141 in relation to lower urinary tract symptoms (LUTS) in a large case-control study nested within the He

142 n the cause of lower urinary tract symptoms (LUTS) in older men.

143 commonly cause lower urinary tract symptoms (LUTS) in the renal transplant (RTx) population.

144 en obesity and lower urinary tract symptoms (LUTS) in the Third National Health and Nutrition Examina

145 actor inducing lower urinary tract symptoms (LUTS) including urinary frequency, urgency and incontine

146 management for lower urinary tract symptoms (LUTS) is limited.

147 main cause of lower urinary tract symptoms (LUTS) may lead to acute urinary retention and need for B

148 g incidence of lower urinary tract symptoms (LUTS) which are increasing.

149 asia (BPH) and lower urinary tract symptoms (LUTS) with excellent, durable functional outcomes.

150 nlargement and lower urinary tract symptoms (LUTS), and it is not clear how sex steroid hormones cont

151 le factors and lower urinary tract symptoms (LUTS), and their relevance in men.

152 IV serostatus, lower urinary tract symptoms (LUTS), behavioral dispositions.

153 Pre-existing lower urinary tract symptoms (LUTS), cognitive impairment, and the high prevalence of

154 he etiology of lower urinary tract symptoms (LUTS), raising the possibility that use of nonsteroidal

155 asia (BPH) and lower urinary tract symptoms (LUTS), recent epidemiological studies suggest that modif

156 Chronic lower urinary tract symptoms (LUTS), such as urgency and incontinence, are common, esp

157 men can cause lower urinary tract symptoms (LUTS), which are increasingly managed with medications.

158 ten results in lower urinary tract symptoms (LUTS).

159 rplasia and/or lower urinary tract symptoms (LUTS).

160 asia (BPH) and lower urinary tract symptoms (LUTS).

161 anisms causing lower urinary tract symptoms (LUTS).

162 ssociated with lower urinary tract symptoms (LUTS).

163 e treatment of lower urinary tract symptoms (LUTS).

164 include other lower urinary tract symptoms (LUTS).

165 asia (BPH) and lower urinary tract symptoms (LUTS).

166 ic, irritative lower urinary tract symptoms (LUTS).

167 p a variety of lower urinary tract symptoms (LUTS).

168 ent of BPH and lower urinary tract symptoms (LUTS).

169 suffering from lower urinary tract symptoms (LUTS).

170 icant BPH with lower urinary tract symptoms (LUTS).

171 rived strains in cell culture suggested that LUTS-associated bacteria are within or extremely closely

172 These LUTS may be masked by low urine output and may pose risk

173 ion within the urinary system contributes to LUTS is unclear.

174 the role of inflammation as a contributor to LUTS remains an interesting hypothesis that requires fur

175 in general, inflammation was not related to LUTS or to benign prostatic hyperplasia progression.

176 ostate surgery could be safely used to treat LUTS/BPH patients.

177 hest BMI ever was positively associated with LUTS (odds ratio = 1.90, 95% confidence interval: 0.89,

178 systemic inflammation may be associated with LUTS and benign prostatic hyperplasia.

179 heart disease was positively associated with LUTS and with irritative symptoms.

180 e (>/=$30,000) was inversely associated with LUTS and with obstructive and irritative symptoms.

181 al care), statin use was not associated with LUTS incidence (hazard ratio = 1.02, 95% confidence inte

182 or diabetes were positively associated with LUTS, and high income (>/=$30,000) was inversely associa

183 : 1.22, 1.96) was positively associated with LUTS.

184 ad been infected with HIV and diagnosed with LUTS.

185 often face a diagnostic dilemma, as men with LUTS secondary to BPH might also present with an elevate

186 gen content and tissue stiffness in men with LUTS.

187 ions as the first-line treatment in men with LUTS.

188 ating obstructed from nonobstructed men with LUTS.

189 rospective study with eligible patients with LUTS and controls over a 3-year period, comparing routin

190 nsuitable for excluding UTI in patients with LUTS.

191 ling in their routine care for patients with LUTS.

192 ated with sexual side effects, patients with LUTS/BPH should be monitored for treatment-related sexua

193 The associations of statin drug use with LUTS incidence and progression were prospectively evalua